Breast tumor patients with high expression of CD47 showed poor survival and prognosis; cGAMP and anti-CD47 combination therapy effectively suppressed tumor growth, whereas monotherapy with anti-CD47 did not inhibit tumors (Kosaka et al., 2021). Here, CD47 is linked to breast neoplasm.